08:01 Mon 14 Dec 2020
N4 Pharma PLC - Holding(s) in Company
14 December 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Holding(s) in Company
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has been notified that Mr.
Enquiries:
N4 Pharma plc |
|
|
Via IFC Advisory |
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44(0)20 3470 0470 |
Nominated Adviser and Joint Broker |
|
|
|
|
|
|
|
Turner Pope Investments (TPI) Limited |
Tel: +44(0)20 3657 0050 |
Joint Broker |
|
|
|
|
|
IFC Advisory Ltd |
Tel: +44(0)20 3934 6630 |
Financial PR |
|
|
|
|
|
|
|
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE